As we finish 2021 we take a look back to everything we’ve accomplished this year and thank everyone who has been supporting our development.
Certainly, 2021 was a very challenging year for everyone, as we had to continuously adapt to all the changes COVID-19 brought upon us. Both 2020 and 2021 will be remembered as the years which caused major disruptions in our society. During these (almost) last two years, we were forced to change the way we interact with each other, the way we conduct business, the way we work, and so many other aspects of our professional and personal lives.
At Inura Medical, the pandemic has also affected our business. As the year comes to an end, we take a look at our accomplishments in 2021, and thank everyone who has been continuously supporting us to reach our most important goal: to improve the lives of women who suffer from OAB!
The last article of this year highlights some of our latest achievements in 2021:
- Closing of our financing round
- Successful conduct of our last pre-clinical studies
- Strengthened our intellectual property position
- Participant in several competitions and programs
Closing of our Pre-Series A financing round
This year we were able to successfully secure CHF 1.5 million in dilutive and non-dilutive funding. The investment proceeds from this round were used to continue our business development and finalize our pre-clinical work. The funds will also be used to prepare for our first-in-human studies. Thanks to this financing round we were able to continue working towards our goal.
The last pre-clinical studies
In May 2021, we started our pre-clinical studies in collaboration with Charles River Laboratories. Thanks to this collaboration we were able to refine our ovulum and successfully conduct our pre-clinical studies, with exciting results. This was the final pre-clinical investigation before we begin the clinical phase I in 2022.
Participation in several competitions and programs
If you follow our social media, you may have seen that Inura Medical has taken part in several different competitions and programs.
For example, Inura Medical was one of the finalists at the Swiss Innovation Challenge. Amongst more than 100 great SMEs and startups (from life sciences and other areas) we were able to secure 12th place in the final ranking. Being one of the finalists was certainly a significant achievement and involved a lot of learning.
We successfully participated in the “100 fürs Baselbiet” program sponsored by the Basellandschaftliche Kantonalbank (BLKB). This allowed us to secure financing which guaranteed continuation of our business development.
The admission into the inQbator Ignite program was also a success for us. The initiative has helped us develop our business strategy and learn from the experiences of other experts in the field.
Intellectual Property (IP)
With the added pre-clinical data we strengthened our IP position. Additionally, in collaboration with our patent attorneys a complete analysis was done of the ongoing patent applications and the strategy for the next steps was planned.
These were some of our major accomplishments of 2021. We look forward to continuing our mission in the next year. We will continue the development of our revolutionary treatment solution aiming for a better quality of life for women suffering from OAB.
Big thank you to everyone who has been supporting us, and see you next year!
About Inura Medical
Inura Medical AG (“Inura”) is a Swiss start-up company with a clear vision to make a difference in women’s health. Inura’s product is an innovative, first-of-a-kind “urethral ovulum” that utilizes a novel route of drug administration to treat diseases of the bladder and lower urinary tract. Inura’s technology results from decades of work in urology by Professor Grant S. Mulholland, a renowned surgeon, academic, and past President of the American Urology Association. The first indication we are addressing with the ovulum is a chronic disease, named overactive bladder (OAB). More details on https://inuramedical.ch/.